See more : Spectra7 Microsystems Inc. (SPVNF) Income Statement Analysis – Financial Results
Complete financial analysis of NFL Biosciences SA (ALNFL.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NFL Biosciences SA, a leading company in the Biotechnology industry within the Healthcare sector.
- VIGO System S.A. (VGO.WA) Income Statement Analysis – Financial Results
- EBET, Inc. (EBET) Income Statement Analysis – Financial Results
- Silver Viper Minerals Corp. (VIPR.V) Income Statement Analysis – Financial Results
- Genesys International Corporation Limited (GENESYS.BO) Income Statement Analysis – Financial Results
- Winnebago Industries, Inc. (WGO) Income Statement Analysis – Financial Results
NFL Biosciences SA (ALNFL.PA)
About NFL Biosciences SA
NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. Its natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 56.06K | 2.24M | 530.73K | 169.36K | 253.87K |
| Gross Profit | -56.06K | -2.24M | -530.73K | -169.36K | -253.87K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.37M | 2.96M | 808.61K | 274.74K | 0.00 |
| Other Expenses | -4.67K | 668.96K | 588.77K | 148.67K | 93.42K |
| Operating Expenses | 4.37M | 668.96K | 588.77K | 148.67K | 93.42K |
| Cost & Expenses | 4.43M | 2.90M | 1.12M | 318.03K | 347.30K |
| Interest Income | 118.55K | 0.00 | 527.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 493.00 | 538.00 | 0.00 | 376.00 |
| Depreciation & Amortization | 56.06K | 52.44K | 43.50K | 41.96K | 43.69K |
| EBITDA | -4.05M | -2.81M | -1.08M | -271.09K | -303.61K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.43M | -3.08M | -901.87K | -318.03K | -347.30K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 318.55K | 221.86K | -217.64K | 4.98K | -375.00 |
| Income Before Tax | -4.11M | -2.86M | -1.12M | -318.03K | -347.67K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -366.39K | -417.83K | -141.27K | -51.54K | -79.71K |
| Net Income | -3.75M | -2.44M | -978.24K | -266.49K | -267.96K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.46 | -0.47 | -0.19 | -0.05 | -0.05 |
| EPS Diluted | -0.46 | -0.47 | -0.19 | -0.05 | -0.05 |
| Weighted Avg Shares Out | 8.11M | 5.23M | 5.23M | 5.23M | 5.23M |
| Weighted Avg Shares Out (Dil) | 8.11M | 5.23M | 5.23M | 5.23M | 5.23M |
Source: https://incomestatements.info
Category: Stock Reports